Boston, MA -- (SBWIRE) -- 08/19/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Merrimack Pharmaceuticals Inc (NASDAQ:MACK), American Realty Capital Properties Inc(NASDAQ:ARCP), Newcastle Investment Corp. (NYSE:NCT), Sequenom, Inc. (NASDAQ:SQNM)
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares dropped 5.38% and closed at $3.34. The company on August 8 announced its second quarter 2013 financial results. Net loss for the second quarter of 2013 was $30.3 million, or basic and diluted net loss per share available to common stockholders of $0.31, compared with net loss for the second quarter of 2012 of $20.1 million, or basic and diluted net loss per share available to common stockholders of $0.22. Collaboration revenues for the second quarter of 2013 were $18.5 million, compared to $12.1 million for the second quarter of 2012, an increase of $6.4 million, or 53%.
How Should Investors Trade MACK After The Recent Volatility? Get Free Report Here
American Realty Capital Properties Inc(NASDAQ:ARCP) shares decreased 1.52% to $12.94. The company, on August 6, announced its operating results for the three and six months ended June 30, 2013. For the quarter ended June 30, 2013, revenues were $45.0 million, compared to $40.2 million in the first quarter of 2013, or a quarter-to-quarter increase of over 11.8%. Funds from operations and adjusted funds from operations totaled $13.6 million and $32.8 million for the second quarter of 2013, respectively, compared to $24.4 million and $30.7 million generated in the quarter ended March 31, 2013, respectively.
How Should Investors Trade ARCP After The Recent Volatility? Get Free Report Here
Newcastle Investment Corp. (NYSE:NCT) shares dropped 0.76% and closed at $5.25. The company on August 7 reported that its second-quarter net income increased to $52.33 million or $0.20 per share, from $29.04 million or $0.21 per share, last year. Core earnings were $43.0 million or $0.16 per share, for the quarter. Income from continuing operations rose to $28.14 million or $0.10 per share, from $23.82 million or $0.17 per share, a year ago. Net interest income decreased to $40.83 million from $48.49 million last year.
Is NCT A Good Buy After The Recent Price Movement? Find Out Here
Sequenom, Inc. (NASDAQ:SQNM) shares closed at $2.98. SQNM and CombiMatrix Corporation (NASDAQ: CBMX), on August 1 jointly announced that the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to broaden and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients.
Is SQNM A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)